'Test And Treat' Strategy For Curbing HIV Draws Questions | WAMU 88.5 - American University Radio

NPR : News

Filed Under:

'Test And Treat' Strategy For Curbing HIV Draws Questions

San Francisco is trying a new tactic to fight AIDS. Health workers are aggressively testing people for HIV and then immediately putting those who test positive on potent antiretroviral drugs.

Known as "test and treat," the approach relies on the fact that taking HIV drugs dramatically reduces a person's risk of transmitting the virus to others. As more and more people are put on medication, the epidemic theoretically should fizzle out.

Test and treat sounds good on paper, but some doctors and policymakers have doubts about its feasibility on a large scale.

An analysis just published in the journal PLOSOne questions whether test and treat is the best strategy in developing countries, such as South Africa, where getting drugs to many people is difficult and the rise of drug resistance is a potential problem.

The results bolster support for the current HIV guidelines set by the World Health Organization, which recommend giving antiretroviral medicines to people whose immune systems are already compromised by the virus.

In 2009, scientists at the WHO developed a mathematical model to look at how test and treat could alter the course of the HIV epidemic in South Africa. The model made a provocative prediction. If all 50 million South Africans could be screened for HIV and the estimated 6 million who are infected given antiretroviral drugs, the number of new HIV cases each year would plummet. The virus would be on its way to elimination.

Mathematical biologist Sally Blower, who co-authored the current study, says this model is too simplistic. It didn't take into account the potential need for expensive, second-line drugs if resistant HIV strains emerge, and it underestimates how long people really stay on the medicines.

When she adds these factors to the model, it predicts that test and treat will take 30 years longer and cost significantly more than originally thought. Plus, focusing treatment on only those who are sick appears cheaper in the long run — and almost as effective at stopping the epidemic in South Africa — as giving drugs to everyone infected.

"Getting 5 million more people treatment, that's kind of a fantasyland," Blower tells Shots. And, she says, it would be tough to sustain. "When you put people on medication, you need to have the resources to keep them on it," she says. Otherwise, resistance can emerge, and it becomes an ethical issue.

Epidemiologist Brian Williams, who helped develop the original WHO model, agrees that sustainability and commitment are key issues. "The worst possibility is to promise people the drugs and then have to take them away," Williams tells Shots.

But he doesn't think this is a reason to dismiss test and treat. "Eventually everybody [who is infected] is going to need the drugs. Why not start their treatment right away," he says. "When you get cancer, you don't wait until it metastasizes to get drugs."

Williams, who now works at South African Centre for Epidemiological Modelling and Analysis, also says it isn't clear whether drugs resistance will be a problem under test and treat. "Experimental evidence suggests that antiretroviral treatment causes drug resistance to go down."

Such questions can't be answered with theoretical models. Treatment strategies need to be evaluated experimentally with small projects, such as the one in San Francisco.

"Each year we are gaining experience and data from countries where treatment scale-up is progressing," Dr. Andrew Ball, a physician at WHO's HIV/AIDS Department, told Shots in an email.

WHO is using the results from these projects and many modeling experiments, to develop new guidelines for antiretroviral drugs. It plans to publish these guidelines in 2013.

In the end, Ball says, eliminating HIV will probably require many strategies in combination with more access to antiretroviral drugs, including more needle exchange programs, condoms and circumcision.

"The issues raised by the new paper are quite valid, and we need to look at them," Ball says. "But the most important information comes from the hard research."

Copyright 2012 National Public Radio. To see more, visit http://www.npr.org/.

NPR

'Passages' Author Reflects On Her Own Life Journey

Gail Sheehy is famous for her in-depth profiles of influential people, as well as her 1976 book on common adult life crises. Now she turns her eye inward, in her new memoir Daring: My Passages.
NPR

Syrup Induces Pumpkin-Spiced Fever Dreams

Hugh Merwin, an editor at Grub Street, bought a 63-ounce jug of pumpkin spice syrup and put it in just about everything he ate for four days. As he tells NPR's Scott Simon, it did not go well.
NPR

Texas Gubernatorial Candidates Go To The Border To Court Voters

Republicans have won every statewide office in Texas for 20 years, but the growing Hispanic population tends to vote Democrat, and the GOP's survival may depend on recruiting Hispanic supporters.
NPR

In San Diego, A Bootcamp For Data Junkies

Natasha Balac runs a two-day boot camp out of the San Diego Supercomputer Center for people from all types of industries to learn the tools and algorithms to help them analyze data and spot patterns in their work.

Leave a Comment

Help keep the conversation civil. Please refer to our Terms of Use and Code of Conduct before posting your comments.